Anthony Goncalves

Summary

Publications

  1. doi request reprint [Not Available]
    Anthony Goncalves
    Departement d Oncologie Medicale, Institut Paoli Calmettes, Marseille, 13009 Centre de recherche en cancérologie de Marseille Institut Paoli Calmettes, Inserm 1068, CNRS 7258, Aix Marseille Universite, Marseille, 13009 Aix Marseille Université, Marseille, 13006 Electronic address
    Bull Cancer 103:S76-89. 2016
  2. doi request reprint [Anticancer drugs: Which prices for therapeutic innovations?]
    Anthony Goncalves
    Institut Paoli Calmettes, Departement d Oncologie Medicale, 13009 Marseille, France Centre de recherche en cancérologie de Marseille institut Paoli Calmettes, Inserm 1068, CNRS 7258, Aix Marseille Universite, 13009 Marseille, France Aix Marseille Université, 13284 Marseille, France Electronic address
    Bull Cancer 103:361-7. 2016
  3. pmc Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment
    Agnès V Tallet
    Department of Radiation Oncology, Institut Paoli Calmettes, Marseille, France
    Radiat Oncol 7:77. 2012
  4. doi request reprint [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]
    Anthony Goncalves
    Institut Paoli Calmettes, Oncologie Médicale, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Bull Cancer 100:453-64. 2013
  5. doi request reprint Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
    Anthony Goncalves
    Oncologie Médicale, Centre de Recherche en Cancerologie de Marseille, INSERM U891, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, Marseille 13000, France
    Anticancer Drugs 20:946-52. 2009
  6. ncbi request reprint Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors
    Marine Gilabert
    Oncologie Médicale, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM U891, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Anticancer Res 31:1079-86. 2011
  7. doi request reprint Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents
    Gais Kadra
    Département de Pharmacologie Moléculaire and U891 INSERM, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France
    Breast Cancer Res Treat 132:1035-47. 2012
  8. doi request reprint [Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers]
    Marine Gilabert
    Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, U891 Inserm, Oncologie Médicale, Marseille, France
    Bull Cancer 97:321-39. 2010
  9. pmc Are there candidates for high-dose chemotherapy in ovarian carcinoma?
    Renaud Sabatier
    Department of Medical Oncology, Institut Paoli Calmettes, 232 Bd Ste Marguerite, Marseille 13273, France
    J Exp Clin Cancer Res 31:87. 2012
  10. doi request reprint Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome
    Renaud Sabatier
    Molecular Oncology Department, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Eur J Cancer 47:1537-45. 2011

Detail Information

Publications64

  1. doi request reprint [Not Available]
    Anthony Goncalves
    Departement d Oncologie Medicale, Institut Paoli Calmettes, Marseille, 13009 Centre de recherche en cancérologie de Marseille Institut Paoli Calmettes, Inserm 1068, CNRS 7258, Aix Marseille Universite, Marseille, 13009 Aix Marseille Université, Marseille, 13006 Electronic address
    Bull Cancer 103:S76-89. 2016
    ..Yet, in both subtypes, whether these substantial improvements may lead to significant benefits in terms of survival and breast conserving surgery remains to be demonstrated. ..
  2. doi request reprint [Anticancer drugs: Which prices for therapeutic innovations?]
    Anthony Goncalves
    Institut Paoli Calmettes, Departement d Oncologie Medicale, 13009 Marseille, France Centre de recherche en cancérologie de Marseille institut Paoli Calmettes, Inserm 1068, CNRS 7258, Aix Marseille Universite, 13009 Marseille, France Aix Marseille Université, 13284 Marseille, France Electronic address
    Bull Cancer 103:361-7. 2016
    ....
  3. pmc Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment
    Agnès V Tallet
    Department of Radiation Oncology, Institut Paoli Calmettes, Marseille, France
    Radiat Oncol 7:77. 2012
    ....
  4. doi request reprint [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]
    Anthony Goncalves
    Institut Paoli Calmettes, Oncologie Médicale, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Bull Cancer 100:453-64. 2013
    ..Recent data indicate that TNBC represent a heterogeneous entity composed of multiple and distinct molecular subtypes, which should deserve specific targeted therapeutics...
  5. doi request reprint Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
    Anthony Goncalves
    Oncologie Médicale, Centre de Recherche en Cancerologie de Marseille, INSERM U891, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, Marseille 13000, France
    Anticancer Drugs 20:946-52. 2009
    ..The subset of HER2-negative, HR-negative (triple-negative) has a very poor outcome, and innovative therapies are eagerly awaited for these patients...
  6. ncbi request reprint Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors
    Marine Gilabert
    Oncologie Médicale, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM U891, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Anticancer Res 31:1079-86. 2011
    ....
  7. doi request reprint Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents
    Gais Kadra
    Département de Pharmacologie Moléculaire and U891 INSERM, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France
    Breast Cancer Res Treat 132:1035-47. 2012
    ..Genomic predictors for Tax- and Ixa-sensitivity can be derived from BTCL and may be helpful for better selecting cytotoxic treatment in BC patients...
  8. doi request reprint [Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers]
    Marine Gilabert
    Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, U891 Inserm, Oncologie Médicale, Marseille, France
    Bull Cancer 97:321-39. 2010
    ..The current techniques applied to clinical samples of breast cancer and the most important results obtained are summarized in this review...
  9. pmc Are there candidates for high-dose chemotherapy in ovarian carcinoma?
    Renaud Sabatier
    Department of Medical Oncology, Institut Paoli Calmettes, 232 Bd Ste Marguerite, Marseille 13273, France
    J Exp Clin Cancer Res 31:87. 2012
    ..Prognosis of advanced ovarian carcinomas (AOC) remains poor with a 5-year survival of 30%. Benefit from high-dose chemotherapy (HDC) in this disease has not been demonstrated to date...
  10. doi request reprint Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome
    Renaud Sabatier
    Molecular Oncology Department, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Eur J Cancer 47:1537-45. 2011
    ..Nevertheless TNBC are heterogeneous in terms of pathological, biological and prognostic behaviours. We explored clinical and pathological factors correlated with outcome in this phenotype...
  11. doi request reprint Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients
    Thierry Bege
    Department of Surgical Oncology, Paoli Calmettes Institute, Regional Comprehensive Cancer Center, Marseille, France
    Ann Surg Oncol 16:856-60. 2009
    ..The risk for short-term postoperative complications related to bevacizumab has been assessed. Late postoperative complications related to bevacizumab have also been suggested by preliminary reports...
  12. pmc Comparative genomic analysis of primary tumors and metastases in breast cancer
    Francois Bertucci
    Département d Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille CRCM, Institut Paoli Calmettes, INSERM UMR1068, CNRS UMR725, Marseille, France
    Oncotarget 7:27208-19. 2016
    ..However, given the rare but potentially relevant divergences for some actionable driver genes, the profiling of metastatic sample is recommended. ..
  13. pmc Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study
    Laurys Boudin
    Departement d Oncologie Medicale, Institut Paoli Calmettes IPC, Marseille, F 13273, France Département d oncologie médicale, Hopital d Instruction des Armees Sainte Anne, Toulon, 83000, France
    J Cancer 7:2077-2084. 2016
    ..These findings provide additional information and options for patients with IBC and who could potentially benefit of HDC-AHSCT...
  14. doi request reprint Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis
    Anthony Goncalves
    Département d Oncologie Médicale and U891 INSERM, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, 232 Bd Ste Marguerite, 13009 Marseille, France
    Breast Cancer Res Treat 127:273-81. 2011
    ..These data demonstrate overexpression of PARP1 in a large number of breast cancers and support the development of PARP inhibitors in basal subtype, but also potentially in other breast cancer subtypes...
  15. doi request reprint Genome profiling of pancreatic adenocarcinoma
    David J Birnbaum
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Genes Chromosomes Cancer 50:456-65. 2011
    ..In conclusion, we have identified novel biomarkers and potential therapeutic targets in pancreatic adenocarcinoma...
  16. pmc Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes
    Anthony Goncalves
    Department of Molecular Pharmacology, Marseille Research Cancer Center, Marseille, France
    Mol Cell Proteomics 7:1420-33. 2008
    ..Our study shows the potential of integrated genomics and proteomics profiling to improve molecular knowledge of complex tumor phenotypes and identify biomarkers with valuable diagnostic or prognostic values...
  17. doi request reprint [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies]
    Thomas Bachelot
    Centre Leon Berard, Oncologie Médicale, 69008 Lyon, France
    Bull Cancer 100:7-14. 2013
    ..Promoting novel targeted approaches and innovative therapeutic combinations is a critical need to improve survival of breast cancer patients with brain metastases...
  18. pmc A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
    Anthony Goncalves
    Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France
    BMC Cancer 8:169. 2008
    ..Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants of cetuximab activity...
  19. doi request reprint Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma
    Pauline Duconseil
    Cancer Research Center of Marseille CRCM, Inserm U1068, CNRS UMR 7258, Aix Marseille University and Paoli Calmettes Institute, Scientific and Technological Park of Luminy, Marseille, France
    Am J Pathol 185:1022-32. 2015
    ..In conclusion, using this approach, we found that transcriptomic analysis could predict the sensitivity to anticancer drugs and the clinical outcome of patients with PDAC...
  20. ncbi request reprint Surgical resection of brain metastases from breast cancer in the modern era: clinical outcome and prognostic factors
    Emeline Tabouret
    Departements of Medical Oncology, Paoli Calmettes Institut, Marseille, France
    Anticancer Res 33:2159-67. 2013
    ..Incidence of brain metastases (BM) from breast cancer (BC) is increasing. However, prognostic evaluation and treatment strategies are still a matter of debate...
  21. pmc BetaHCG secretion by a pulmonary adenocarcinoma
    Cecile Vicier
    Department of Medical Oncology, Institut Paoli Calmettes, 13009 Marseille, France
    World J Surg Oncol 11:228. 2013
    ..This secretion decreased with tumor response to chemotherapy. Only a few reports of paraneoplastic BetaHCG secretion can be found in the literature for several different cancers. ..
  22. ncbi request reprint Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors
    Anthony Goncalves
    Department of Medicine, Institut Paoli Calmettes, 13273 Marseille, France
    Clin Cancer Res 9:102-8. 2003
    ..The purpose of our study was to assess the feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when administered with granulocyte colony-stimulating factor (G-CSF) support every 3 weeks...
  23. pmc Assessment of prognostic scores in brain metastases from breast cancer
    Emeline Tabouret
    APHM, Timone Hospital, Departement of Neuro Oncology, Marseille, France E T L institut Paoli Calmettes, Department of Medical Oncology, Marseille, France E T, A G APHM, Timone Hospital, Department of Neurosurgery, Marseille, France P M L institut Paoli Calmettes, Department of Biostatistics, Marseille, France B E UMR911, CRO2, Aix Marseille Universite, Marseille, France P M L institut Paoli Calmettes, Department of Anatomic Pathology, Marseille, France E C J L institut Paoli Calmettes, Department of Radiotherapy, Marseille, France A T
    Neuro Oncol 16:421-8. 2014
    ..We evaluated the prognostic value and validity of the 6 proposed scoring systems in an independent population of BC patients with BM...
  24. doi request reprint Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation
    Laurys Boudin
    Departement d Oncologie Medicale, Institut Paoli Calmettes IPC, Marseille, F 13273, France
    Eur J Cancer 57:118-26. 2016
    ....
  25. pmc Association of carcinoid tumor and low grade glioma
    Emeline Tabouret
    Departement d Oncologie Medicale, Institut Paoli Calmettes, 232 Boulevard Ste Marguerite, 13009 Marseille, France
    World J Surg Oncol 10:236. 2012
    ..Lung carcinoid tumor and low grade glioma are two uncommon malignancies...
  26. ncbi request reprint METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors
    Simon Launay
    Department of Oncology, Institut Paoli Calmettes, Marseille, France Centre de Recherche en Cancerologie de Marseille, Inserm U1068, CNRS U7258, Marseille, France Aix Marseille Université, Marseille, France
    Anticancer Res 36:293-9. 2016
    ..The present monocentric and prospective phase 1 study evaluated the safety of a metronomic chemotherapy in refractory tumors...
  27. pmc Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib
    Marine Gilabert
    Institut Paoli Calmettes, Department of Molecular Pharmacology, Marseille, France Institut Paoli Calmettes, Department of Medical Oncology, Marseille, France Aix Marseille University, Marseille, France Centre de Recherche en Cancerologie de Marseille, U1068 Inserm, U7258 CNRS, Marseille, France
    PLoS ONE 9:e104302. 2014
    ..To identify specific biomarkers of BCSCs, we have performed comparative proteomics of BCSC-enriched and mature cancer cell populations from the human breast cancer cell line (BCL), BrCA-MZ-01...
  28. doi request reprint [Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting]
    Anthony Goncalves
    Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Oncologie Médicale, Aix Marseille Universite, Inserm U1068, CNRS U7258, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Bull Cancer 100:1295-310. 2013
    ....
  29. ncbi request reprint [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications]
    Anthony Goncalves
    Centre de Recherche en Cancerologie de Marseille, Département de Pharmacologie Moléculaire, Institut Paoli Calmettes IPC et Inserm UMR 599, Marseille, France
    Med Sci (Paris) 23:23-6. 2007
    ..Proteomic technologies, including SELDI-TOF (surface enhanced laser desorption/ionization-time of flight) mass spectrometry, are emerging tools that may contribute to better reach these key objectives...
  30. ncbi request reprint Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer
    Carole Perez-Ellis
    INSERM, U912, Marseille, France
    Am J Clin Oncol 32:492-8. 2009
    ..We carried out the first cost-effectiveness study for Trastuzumab in MBC patients, in France, that is based on observed resource use and outcomes in clinical practice...
  31. doi request reprint How may targeted proteomics complement genomic data in breast cancer?
    Mathilde Guerin
    a Aix Marseille Univ, CNRS, INSERM, Institut Paoli Calmettes, CRCM, Marseille Protéomique, Marseille, France
    Expert Rev Proteomics 14:43-54. 2017
    ..Expert commentary: These different targeted proteomic approaches, able to complement genomic data in BC and characterize tumors more precisely, will permit to go through a more personalized treatment for each patient and tumor...
  32. doi request reprint [Small HER2-positive breast cancer: which prognosis and which adjuvant treatment?]
    Anthony Goncalves
    Institut Paoli Calmettes, Oncologie Médicale, 232, boulevard Sainte Marguerite, 13009 Marseille, France, Inserm U1068, CNRS U7258, Aix Marseille Universite, Centre de Recherche en Cancerologie de Marseille, 27, boulevard Lei Roure, 13009 Marseille, France
    Bull Cancer 100:847-56. 2013
    ....
  33. doi request reprint Reassessment of scoring systems and prognostic factors for metastatic spinal cord compression
    Emeline Tabouret
    Department of Medical Oncology, Institut Paoli Calmettes, 232 Bd de Sainte Marguerite, 13009 Marseille, France
    Spine J 15:944-50. 2015
    ..The incidence of metastatic spinal cord compression (MSCC) is increasing, paralleling increasing life expectancy of patients. However, management of MSCC and relevance of scoring systems remain controversial...
  34. ncbi request reprint BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer
    Jinghua Qiu
    Institut Paoli Calmettes, Marseille, France
    Cancer Genomics Proteomics 8:15-8. 2011
    ..The impact of BRAF V600E mutation is not well documented...
  35. ncbi request reprint Lung cancer in elderly patients: a retrospective analysis of practice in a single institution
    Anne Madroszyk-Flandin
    Department of Medicine, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, 13273 Marseille Cedex 9, France
    Crit Rev Oncol Hematol 64:43-8. 2007
    ..6, ND) and 5.7 months (95%; 4.2-9.6) for stage IIIB and IV, respectively. Toxicities were judged acceptable with 19 hospitalizations after chemotherapy, for 16 patients who represent 34.8% of patients who received chemotherapy...
  36. doi request reprint [PARP inhibitors and breast cancer: update and perspectives]
    Anthony Goncalves
    Institut Paoli Calmettes, Oncologie Médicale, Marseille, France
    Bull Cancer 99:441-51. 2012
    ....
  37. pmc Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
    Emilie Mamessier
    Centre de Recherche en Cancerologie de Marseille, INSERM UMR U891, Marseille, France
    J Clin Invest 121:3609-22. 2011
    ..This highlights the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitumor immunity...
  38. doi request reprint [Metastatic colorectal cancers and targeted therapy against EGFR]
    Frederic Viret
    Département d Oncolgie Médicale, Institut Paoli Calmettes Marseille, Centre CRCM, INSERM, Unité 891, Universite de la Mediterranee, 27, boulevard Lei Roure, 13009 Marseille, France
    Med Sci (Paris) 25:13-21. 2009
    ..Such improvements should continue to lead to increased cure rates in early disease and better overall survival in advanced cases...
  39. ncbi request reprint [G-CSF in oncology]
    Frederic Viret
    Departement d Oncologie Medicale, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, 13273 Marseille Cedex 09
    Bull Cancer 93:463-71. 2006
    ..This article reviews the data supporting the clearly clinical applications of CSFs in oncology...
  40. doi request reprint Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis
    Renaud Sabatier
    Department of Oncology, Institut Paoli Calmettes, Marseille, France Centre de Recherche en Cancerologie de Marseille, Inserm U1068, CNRS U7258, Marseille, France Aix Marseille Université, Marseille, France
    Breast 27:8-14. 2016
    ..Our objective was to describe IDCPIC's clinicopathological and prognostic features and compare them to that of invasive ductal carcinoma without predominant intraductal component (IDC)...
  41. pmc Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study
    Anthony Goncalves
    Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France
    Oncotarget 7:79428-79441. 2016
    ..We conducted a pilot study to evaluate whether precision medicine could be prospectively implemented for aBC patients in a single center and to examine whether patient-derived tumor xenografts (PDX) could be obtained in this population...
  42. doi request reprint [Management of brain metastases for lung cancer patients]
    Fabrice Barlesi
    Aix Marseille Universite, Assistance Publique Hopitaux de Marseille, Service d Oncologie Multidisciplinaire et Innovations Thérapeutiques, Hopital Nord, Chemin des Bourrelly, 13915 Marseille Cedex 20, France
    Bull Cancer 100:303-8. 2013
    ..The management will depend on the circumstances of diagnosis (symptomatic or not), the cancer history (synchronous or metachronous brain metastases), the histology and the number of lesions...
  43. doi request reprint Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery
    Francois Bertucci
    Institut Paoli Calmettes and UMR599, Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, 232, Bd Sainte Marguerite 13009 Marseille, France
    Future Oncol 4:271-87. 2008
    ..The different techniques currently applied to clinical samples of breast cancer and the most important results obtained are summarized in this review...
  44. doi request reprint [Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients]
    Patricia Marino
    Institut Paoli Calmettes, Marseille, France
    Med Sci (Paris) 28:19-23. 2012
    ..We also discuss some of the issues related to the regulatory decisions (pricing and reimbursement) concerning the test/drug couple...
  45. doi request reprint [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option]
    Marine Gilabert
    Institut Paoli Calmettes, Oncologie Médicale, 232, boulevard de Sainte Marguerite, 13008 Marseille, France, Inserm U1068 CNRS U7258, Universite Aix Marseille, Centre de Recherche en Cancerologie de Marseille, Faculté des sciences de Lumigny, 163, Avenue de Luminy, 13009 Marseille, France
    Bull Cancer 101:325-33. 2014
    ....
  46. ncbi request reprint Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma
    Gilles Houvenaeghel
    Department of Surgery, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, Marseilles, France
    Gynecol Oncol 100:338-43. 2006
    ..To report the long-term survival of 35 patients who underwent surgery after concomitant chemoradiation for locally advanced cervical cancers...
  47. doi request reprint Clinical application of proteomics in breast cancer: state of the art and perspectives
    Anthony Goncalves
    Centre de Recherche en Cancerologie de Marseille, Département de Pharmacologie Moléculaire, Institut Paoli Calmettes et UMR599 Inserm, Marseille, France
    Med Princ Pract 20:4-18. 2011
    ..Despite their current limits, these pioneering techniques are promising. The most important results as well as the current limitations and perspectives are summarized and discussed...
  48. doi request reprint [Systemic learning planification for medical students during oncology clinical rotation]
    Anthony Goncalves
    Institut Paoli Calmettes, Departement d Oncologie Medicale, Marseille, France
    Bull Cancer 98:1489-508. 2011
    ....
  49. pmc A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor
    Odile Gayet
    Centre de Recherche en Cancérologie de Marseille CRCM, Inserm U1068, CNRS UMR 7258, Aix Marseille Université and Institut Paoli Calmettes, Parc Scientifique et Technologique de Luminy, Marseille, France
    Oncotarget 6:746-54. 2015
    ..In conclusion, we present data obtained with the well-known drug 5-aza-dC as a proof of concept that a drug that seems to be inefficient in solid tumors in general could be applicable to a particular subgroup of patients with PDAC. ..
  50. pmc MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
    Emeline Tabouret
    Institut Paoli Calmettes, Medical Oncology Department, Marseille, France
    Oncotarget 7:18531-40. 2016
    ..We examined the prognostic impact of MMP2 and MMP9 serum levels in BEVERLY-2 patients...
  51. ncbi request reprint The ErbB2 signaling network as a target for breast cancer therapy
    Ali Badache
    UMR599 Inserm, Centre de Recherche en Cancerologie de Marseille, 27 Bd Lei Roure, 13009 Marseille, France
    J Mammary Gland Biol Neoplasia 11:13-25. 2006
    ....
  52. ncbi request reprint Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour
    Francois Bertucci
    Departement d Oncologie Medicale, Institut Paoli Calmettes, 13009 Marseille, France
    Oncol Rep 16:97-101. 2006
    ..Such a approach, far less invasive than surgery and combined with sequencing, will likely help in better tailoring the treatment of advanced GISTs and understanding the mechanisms of resistance and response to imatinib...
  53. ncbi request reprint Proteomics of breast cancer: principles and potential clinical applications
    Francois Bertucci
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes, IPC, and UMR599 INSERM, 13009 Marseille, France
    Mol Cell Proteomics 5:1772-86. 2006
    ....
  54. ncbi request reprint [Therapeutic implications of advances in breast cancer biology]
    Francois Bertucci
    Departement d Oncologie Medicale, Département d Oncologie Moléculaire, Institut Paoli Calmettes, IFR57, 13273 Marseille 09
    Rev Prat 54:865-70. 2004
    ..This stratification should make it possible to better tailor the treatment and boost the discovery of new therapeutic targets..
  55. ncbi request reprint Retinoids, cisplatin and interferon-alpha in recurrent or metastatic cervical squamous cell carcinoma: clinical results of 2 phase II trials
    Anne Chantal Braud
    Department of Medicine, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, 13273 Marseille Cedex 9, France
    Eur Cytokine Netw 13:115-20. 2002
    ....
  56. ncbi request reprint Recent trends in epidemiology of brain metastases: an overview
    Emeline Tabouret
    AP HM, Timone Hospital, Departement of Neuro oncology and Neuro surgery, Marseille, France
    Anticancer Res 32:4655-62. 2012
    ..The recent emergence of targeted therapies and growing knowledge regarding the specific biology of BM should allow further improvements in prognosis of this devastating disease...
  57. pmc Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer
    Anne Catherine Lhoumeau
    CRCM, Team Cell Polarity, Cell signalling and Cancer Equipe labellisée Ligue Contre le Cancer, INSERM, U1068, Marseille, F 13009, France Institut Paoli Calmettes, Marseille, F 13009, France Aix Marseille Université, Marseille, F 13284, France CNRS, UMR7258, F 13009, Marseille, France Department of Biopathology, Institut Paoli Calmettes, Marseille, France
    PLoS ONE 10:e0123768. 2015
    ..PTK7 expression thus represents a potential prognostic biomarker and a novel therapeutic target in CRC. ..
  58. doi request reprint Personalized medicine: present and future of breast cancer management
    Renaud Sabatier
    Oncologie Médicale, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Inserm U1068, CNRS U7258, Aix Marseille Universite, Marseille, France Electronic address
    Crit Rev Oncol Hematol 91:223-33. 2014
    ..In this review, we present the advances in treatment personalization which are currently used in daily practice as well as the technologies and therapies under investigation in various clinical trials. ..
  59. doi request reprint [Systemic treatments of inflammatory breast cancer: an overview]
    Audrey Monneur
    Institut Paoli Calmettes, Oncologie Médicale, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Bull Cancer 101:1080-8. 2014
    ..All those treatments have been extrapolated from standard breast cancers. Thus, a deep molecular knowledge of IBC appears to be critical in order to develop specific treatments effectively targeting its particular aggressiveness. ..
  60. doi request reprint [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]
    Anthony Goncalves
    Institut Paoli Calmettes, Oncologie Médicale, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Bull Cancer 99:1183-91. 2012
    ..T-DM1 appears to be an effective therapeutic option to treat patients with HER2-positive metastatic breast cancer...
  61. pmc Eribulin targets a ch-TOG-dependent directed migration of cancer cells
    Brice Chanez
    Centre de Recherche en Cancerologie de Marseille, INSERM, Marseille, France
    Oncotarget 6:41667-78. 2015
    ..Our data suggest that eribulin binding to the tip of microtubules and subsequent loss of ch-TOG is a priming event leading to alterations in microtubule dynamics and cancer cell migration. ..
  62. doi request reprint [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]
    Mathilde Guerin
    Institut Paoli Calmettes, Oncologie Médicale, 232, boulevard Ste Marguerite, 13009 Marseille, France Inserm U1068 CNRS U7258, Aix Marseille Universite, Centre de Recherche en Cancerologie de Marseille, 13009 Marseille, France
    Bull Cancer 102:390-7. 2015
    ..1 months in the lapatinib-capecitabine arm versus 30.9 months in the trastuzumab emtansine arm (HR=0.68; 95% CI=0.55-0.85, P<0.001). Moreover, adverse events were more frequent in the lapatinib-capecitabine arm. ..
  63. doi request reprint [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers]
    Renaud Sabatier
    Oncologie Médicale, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Inserm U1068, CNRS U7258, Aix Marseille Universite, Marseille, France
    Bull Cancer 101:765-71. 2014
    ..This drug has already been evaluated in the neoadjuvant setting with a FDA approval recently obtained. Its use in the adjuvant setting is under evaluation. ..
  64. ncbi request reprint A serum protein signature with high diagnostic value in bacterial endocarditis: results from a study based on surface-enhanced laser desorption/ionization time-of-flight mass spectrometry
    Florence Fenollar
    Unite des Rickettsies, Centre National de la Recherche Scientifique 6020, Institut Federatif de Rechercher 48, Faculte de Medecine, Marseille, France
    J Infect Dis 194:1356-66. 2006
    ..Surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS) based on serum protein profiling is a powerful approach that can generate biomarkers with diagnostic value...